<?xml version="1.0" encoding="UTF-8"?>
<p>On September 19, 2002, the Treatment Action Campaign and South Africaâ€™s Competition Commission filed a lawsuit against GlaxoSmithKline and Boehringer Ingelheim. These two companies were accused of charging exorbitant prices for ritonavir, lamivudine, and nevirapine. GlaxoSmithKline and Boehringer Ingelheim were also found guilty of violating the Competition Act of 1998, abusing their high-standing positions in the ARV markets, denying competitors access to an essential facility, and engaging in an exclusionary act. The terms of the final settlement required the two pharmaceutical companies to extend the voluntary license granted to Aspen Pharmacare to the public and private sectors in October of 2001. This action granted up to three more voluntary licenses on the same terms as those given to Aspen Pharmacare, permitted the export of ARVs to sub-Saharan African countries, and charged royalties of no more than 5% of the net sales of the relevant ARV drugs. This settlement marked an historic victory in the struggle of developing countries fighting against multinational pharmaceutical enterprises using the patent to establish a profitable monopoly over the industry [
 <xref ref-type="bibr" rid="CR13">13</xref>].
</p>
